Amlodipine - A New Calcium-Channel Blocker
Superseded by Treatment Guidelines "Drugs for Postmenopausal Osteoporosis" - Issue 111, November 1, 2011
Amlodipine (am loe' di peen) besylate (Norvasc - Pfizer), a dihydropyridine calcium-channel blocker, has been approved by the US Food and Drug Administration for once-daily oral treatment of hypertension, chronic stable angina, and vasospastic (Prinzmetal's) angina....
Amlodipine (am loe' di peen) besylate (Norvasc - Pfizer), a dihydropyridine calcium-channel blocker, has been approved by the US Food and Drug Administration for once-daily oral treatment of hypertension, chronic stable angina, and vasospastic (Prinzmetal's) angina....
Cannot Access - We are sorry, but you cannot access the requested article.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
Information about the article:
Title: Amlodipine - A New Calcium-Channel Blocker
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 882
Article Code: 882a
Date: October 30, 1992
Volume: 34
Pages: 99-100
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 882
Article Code: 882a
Date: October 30, 1992
Volume: 34
Pages: 99-100
Subscribe to The Medical Letter on Drugs and Therapeutics for instant access to this article. Add this downloadable, electronic article to your cart (U.S. English version only)